TY - JOUR
TI - Evaluation of DNA ploidy in relation with established prognostic factors
in patients with locally advanced (unresectable) or metastatic
pancreatic adenocarcinoma: a retrospective analysis
AU - Tsavaris, Nikolas
AU - Kavantzas, Nicolaos
AU - Tsigritis, Kostantinos and
AU - Xynos, Ioannis D.
AU - Papadoniou, Nikitas
AU - Lazaris, Andreas and
AU - Kosmas, Christos
AU - Agrogiannis, George
AU - Dokou, Anna
AU - Felekouras,
AU - Evangelos
AU - Antoniou, Efstathios
AU - Polyzos, Aris
AU - Sarantonis,
AU - John
AU - Tsipras, Heracles
AU - Karatzas, Gavrilos
AU - Papalambros,
AU - Alexandros
AU - Patsouris, Efstratios S.
JO - BMC Cancer
PY - 2009
VL - 9
TODO - null
SP - null
PB - BMC
SN - 1471-2407
TODO - 10.1186/1471-2407-9-264
TODO - null
TODO - Background: Most patients with ductal pancreatic adenocarcinoma are
diagnosed with locally advanced (unresectable) or metastatic disease.
The aim of this study was to evaluate the prognostic significance of DNA
ploidy in relation with established clinical and laboratory variables in
such patients.
Methods: Two hundred and twenty six patients were studied
retrospectively. Twenty two potential prognostic variables
(demographics, clinical parameters, biochemical markers, treatment
modality) were examined.
Results: Mean survival time was 38.41 weeks (95% c.i.: 33.17-43.65),
median survival 27.00 weeks (95% c.i.: 23.18-30.82). On multivariate
analysis, 10 factors had an independent effect on survival: performance
status, local extension of tumor, distant metastases, ploidy score,
anemia under epoetin therapy, weight loss, pain, steatorrhoea, CEA, and
palliative surgery and chemotherapy. Patients managed with palliative
surgery and chemotherapy had 6.7 times lower probability of death in
comparison with patients without any treatment. Patients with ploidy
score > 3.6 had 5.0 times higher probability of death in comparison with
patients with ploidy score < 2.2 and these with ploidy score 2.2-3.6 had
6.3 times higher probability of death in comparison with patients with
ploidy score < 2.2.
Conclusion: According to the significance of the examined factor,
survival was improved mainly by the combination of surgery and
chemotherapy, and the presence of low DNA ploidy score.
ER -